The use of fetal bovine acellular dermal matrix for management of chronic wounds

Yıl 2023, Cilt: 6 Sayı: 4, 713 - 719, 30.07.2023

Tuna Gümüş

https://doi.org/10.32322/jhsm.1261658

Öz

Aims: In the treatment of chronic wounds, tissue growth must be addressed and optimized. The purpose of this study is to investigate the use of the regenerative medicinal product Fetal Bovine Acellular Dermal Matrix (FBADM) in chronic wounds.
Methods: The patients were chosen sporadically and randomly based on availability to FBADM. Patients were assessed for adequate perfusion, debridement was performed, and wounds were ensured to be free of infection. FBADM was placed in the wound bed covered with a non-adherent contact layer, and a hydrogel sheet was placed to maintain adequate moisture. Offloading or compression was used as clinically indicated. Patients were then followed weekly. Digital photography was used to visually document healing progress.
Results: After 1-3 weeks wounds managed with FBADM had improved characteristics and healthy vascularized tissue that subsequently epithelialized from wound margins or grafted with split thickness skin grafts. Of the 14 wounds we achieved 69% complete healing, 24% non-complete healing after 12 weeks of FBADM application. 7% of the wounds needed skin graft surgery.
Conclusion: We found FBADM to be useful for treatment regimen of diabetic foot and leg ulcers, venous leg ulcers, surgical wounds, and wounds being prepared for skin grafting.

Anahtar Kelimeler

Chronic wounds, extracellular matrix, tissue engineering, skin substitutes

Destekleyen Kurum

Wake Forest University School of Medicine

Proje Numarası

00033880

Teşekkür

Cover letter Dear editor; In this article subjects have been retrospectively evaluated after obtaining IRB approval from Wake Forest School of Medicine ethics committee. Ethics committee approval State IRB number is: IRB00033880. In figures there is no information or evidence to reveal the identities of the participants in the study. The name of the submitted article is “The Use of Fetal Bovine Acellular Dermal Matrix for Management of Chronic Wounds”. This study is conducted in Wake Forest University Wound Care and Hyperbaric Medicine center in USA and article is not published elsewhere and is not being process of being evaluated in another journal at the same time. Conflict of Interest Statement: The authors have no conflicts of interest to declare. Financial Disclosure: The authors declared that this study has received no financial support. Author Contributions: All of the authors declare that they have all participated in the design, execution, and analysis of the paper, and that they have approved the final version. Tuna Gümüş Department of Undersea and Hyperbaric Medicine, University of Health Sciences, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkey Principal author: Tuna Gümüş Corresponding author: Tuna Gümüş, Department of Undersea and Hyperbaric Medicine, University of Health Sciences, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkey E mail: [e-mail] Mailing Address: Kartal Dr. Lutfi Kirdar Sehir Hastanesi, 34865, Istanbul / Turkey Mobile: [phone] Fax: [phone]

Kaynakça

• Hayn E. Successful treatment of complex traumatic and surgical wounds with a foetal bovine dermal matrix. Int Wound. 2014;11(6):675-680. doi: 10.1111/iwj.12028. Epub 2013 Mar 4.
• James S A Neill, William C Lineaweaver. Tissue response to bovine fetal collagen extracellular matrix in full-thickness skin wounds. Am J Clin Pathol. 2013;140(2):248-252. doi: 10.1309/AJCPMF3B9XJAKXKM.3.
• Monaco JL., Lawrence WT. Acute wound healing an overview. Clin Plast Surg. 2003;30(1):1-12. doi: 10.1016/s0094-1298(02)00070-6.
• Herndon DN, Nguyen TT, Gilpin DA. Growth factors. Local and systemic. Arch Surg. 1993;128(11):1227-1233. doi: 10.1001/archsurg.1993.01420230055009.
• Wang D, Chen H, Lei L, et al. Biofabricated macrophage and fibroblast membranes synergistically promote skin wound healing. Bioeng Transl Med. 2022;7(3):e10344. doi:10.1002/btm2.10344
• P Martin, J Hopkinson-Woolley, J McCluskey. Growth factors and cutaneous wound repair. Prog Growth Factor Res. 1992;4(1):25-44. doi: 10.1016/0955-2235(92)90003-z.
• Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH. Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta. J Exp Med. 1987;165(1):251-256. doi:10.1084/jem.165.1.251
• Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002;3(5):349-363. doi:10.1038/nrm809
• Golinko MS, Clark S, Rennert R, et al. Wound emergencies: the importance of assessment, documentation, and early treatment using a wound electronic medical record. Ostomy Wound Manag. 2009;55:54.
• Armstrong DG, Gurtner GC. A histologically hostile environment made more hospitable? Nat Rev Endocrinol. 2018;14:511.
• Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017;376:2367.
• Kirsner RS, Bohn G, Driver VR, et al. Human acellular dermal wound matrix: evidence and experience. Int Wound J. 2015;12(6):646-654. doi:10.1111/iwj.12185
• Brigido SA, Schwartz E, McCarroll R, Hardin-Young J. Use of an acellular flowable dermal replacement scaffold on lower extremity sinus tract wounds: a retrospective series. Foot Ankle Spec. 2009;2(2):67-72. doi:10.1177/1938640009333474
• Jeon M, Kim SY. Application of a paste-type acellular dermal matrix for coverage of chronic ulcerative wounds. Arch Plast Surg. 2018;45(6):564-571. doi:10.5999/aps.2018.00605
• Marston WA, Hanft J, Norwood P, Pollak R; Dermagraft Diabetic Foot Ulcer Study Group. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care. 2003;26(6):1701-1705. doi:10.2337/diacare.26.6.1701
• Nicholas MN, Yeung J. Current Status and Future of Skin Substitutes for Chronic Wound Healing. J Cutan Med Surg. 2017;21(1):23-30. doi:10.1177/1203475416664037
• Zelen CM, Serena TE, Gould L, et al. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost. Int Wound J. 2016;13(2):272-282. doi:10.1111/iwj.12566
• Karr JC. Retrospective comparison of diabetic foot ulcer and venous stasis ulcer healing outcome between a dermal repair scaffold (PriMatrix) and a bilayered living cell therapy (Apligraf) Advances in Skin & Wound Care. 2011;24(3):119–125.
• Lullove E. Acellular fetal bovine dermal matrix in the treatment of nonhealing wounds in patients with complex comorbidities. J Am Pediatr Med Assoc. 2012;102(3):233–239.
• Kavros SJ. Acellular fetal bovine dermal matrix for treatment of chronic ulcerations of the midfoot associated with charcot neuroarthropathy. Foot & Ankle Specialist. 2012;5(4):230–234.
• Clark RA, Ghosh K, Tonnesen MG. Tissue engineering for cutaneous wounds. J Invest Dermatol. 2007; 127(5): 1018-1029.
• Schultz GS, Wysocki A. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen. 2009;17(2):153-162.
• Gibson D, Cullen B, Legerstee R, et al. MMPs Made Easy. Wounds Int. 2009; 1(1).
• Nataraj C, Ritter G, Dumas S, et al. Extracellular wound matrices: novel stabilisation and sterilisation method for collagen-based biologic wound dressings. Wounds. 2007; 19(6):148-156.
• Hodde JP, Hiles MC. Bioactive FGF-2 in sterilized extracellular matrix. Wounds. 2001;13(5):195-201.
• Wiegland C, Abel M, Ruth P, Hipler UC. Influence of the collagen origin on the binding affinity for neutrophil elastase. Abstract presented at: 18th Conference of the European Wound Management Association (EWMA); May 14-16, 2008.
• Mulder G, Lee DK. A retrospective clinical review of extracellular matrices for tissue reconstruction: equine pericardium as a biological covering to assist with wound closure. Wounds. 2009;21(9):254-61.
• Cornwell KG, Landsman A, James KS. Extracellular matrix biomaterials for soft tissue repair. Clinics in Podiatric Medicine and Surgery vol. 26, no. 4, pp. 2009:507–23.
• Limova M. Active wound coverings: bioengineered skin and dermal substitutes. Surg Clin North Am. 2010; ;90(6):1237-1255.
• Wilson GJ, Courtman DW, Klement P, Michael Lee J, Yeger H. Acellular matrix: a biomaterials approach for coronary artery bypass and heart valve replacement. Ann Thorac Surg. 1995;60:353-358.
• Onesti MG, Carella S, Maruccia M, Marchese C, Fino P, Scuderi N. A successful combined treatment with dermal substitutes and products of regenerative medicine in a patient affected by extravasation injury from hypertonic solution. In Vivo 2012;26(1):139-142.
• Smith LT, Holbrook KA, Madri JA. Collagen types I, III, and V in human embryonic and fetal skin. Am J Anat. 1986;175:507–521.
• Sykes B, Puddle B, Francis M, Smith R. The estimation of two collagens from human dermis by interrupted gel electrophoresis. Biochem Biophys Res Commun. 1976;72:1472–1480.
• Postlethwaite AE, Seyer JM, Kang AH. Chemotactic attraction of human fibroblasts to type I, II, and III collagens and collagen-derived peptides. Proc Natl Acad Sci U S A. 1978;75:871–875.
• Liu X, Wu H, Byrne M, Krane S, Jaenisch R. Type III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development. Proc Natl Acad Sci U S A. 1997;94:1852–1856.
• Wanitphakdeedecha R, Chen TM, Nguyen TH. The use of acellular, fetal bovine dermal matrix for acute, full-thickness wounds. J Drugs Dermatol. 2008;7:781–784.
• Cornwell KG, Landsman A, James KS. Extracellular matrix biomaterials for soft tissue repair. Clin Podiatr Med Surg. 2009;26(4):507-523. doi:10.1016/j.cpm.2009.08.001